Filter the drugs by the phase of research, how they help and the responsive mutations.
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene. Browse the
database of
drugs treating specific mutations compiled by the AIM tool.
| Drug | Marketed as | Description | Phase of research | How it helps |
|---|---|---|---|---|
| NB30 | Aminoglycoside capable of translational readthrough |
Pre-clinical | Restore CFTR Function | |
| NB54 | Aminoglycoside capable of translational readthrough |
Pre-clinical | Restore CFTR Function | |
| NCI118208 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| NCI130813 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| NCI407882 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| NCI73100 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| NS004 | Enhances CFTR activity |
Pre-clinical | Restore CFTR Function | |
| Nitric oxide | Gas with antimicrobial properties |
Phase Two Clinical Trial | Anti-Infective | |
| OligoG | Decreases the thickness of mucus in the lungs |
Phase Two Clinical Trial | Mucociliary Clearance | |
| Omalizumab | Xolair® | Treats CF-related allergic bronchopulmonary aspergillosis |
FDA-/EMA-approved for Other Purpose | Nutritional-GI-Other |
